MYLUNG Consortium: characterizing barriers to comprehensive biomarker testing, an interview with Makenzi Evangelist

Written by Makenzi Evangelist

MYLUNG trial, data, asco

Data from the MYLUNG ConsortiumTM Protocol 1 was recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (4−8 June 2021). In this interview we explore how the study aims to characterize real world barriers to timely and comprehensive biomarker testing in order to identify meaningful interventions. Could you explain why molecular testing and targeted therapy is particularly important for the treatment of metastatic NSCLC? Biomarker testing is critical to ensuring patients have access to the most effective treatments for their lung cancer as well as the opportunity to receive emerging therapies in the context of a clinical...

To view this content, please register now for access

It's completely free